News & Updates

Asians with extremely high or low fat mass index (FMI) and fat-free mass index (FFMI) are at increased risk of mortality, suggests a study. However, the associations of FMI and FFMI with the mortality risk differ across subgroups and causes of death.

Individuals with type 2 diabetes (T2D) who have high blood pressure (BP) levels are at increased risk of death from cardiovascular disease (CVD), according to a large registry cohort in Singapore. However, the risk increase is also present for those who have low diastolic BP.

Twelve-month treatment with zoledronate significantly increases bone mineral density (BMD) Z-scores without affecting growth in nonambulant children with cerebral palsy (CP), reports a study. However, side effects of the first dose are common.

Serum levels of remnant cholesterol may be used to assess an individual’s susceptibility to developing nonalcoholic fatty liver disease (NAFLD), independent of traditional lipid profiles, suggests a recent study.

Treatment with dapagliflozin results in a lower risk of worsening heart failure (HF) or cardiovascular death and improvements in symptoms among patients with HF and type 2 diabetes (T2D), with or without neuropathy, according to a study presented at AHA 2023. However, the beneficial effects of dapagliflozin appears more evident in those with neuropathy.